Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
225Ac-J591 Re-treatment in mCRPC
NCT04576871Phase 1Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Oct 2020
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CONV01-α in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Weill Cornell Medicine. Primary endpoint: Change in the proportion of subjects in assessing safety of 225Ac-J591. Started Oct 2020; status: completed.
02
Drugs
CONV01-α
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04576871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04576871.